Source: Annual Congress 2009 - Clinical immunology of tuberculosis
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
C. Sevinc, P. Mutlu, O. Kilinc, G. Can, N. Akkoc, E. S. Ucan (Izmir, Turkey). Our approach about latent tuberculosis infection in patients who are given anti-TNF alpha therapy. Eur Respir J 2009; 34: Suppl. 53, 2562

Member's Comments

No comment yet.

Related content which might interest you: Isoniazid hepatotoxicity associated with treatment of latent tuberculosis in patients on anti-TNF treatment Source: Annual Congress 2007 - Clinical tuberculosis Year: 2007 A choice of regimen improves completion for patients with latent TB infection Source: Breathe 2008; 4: 366 Year: 2008 Benefit of treatment of latent tuberculosis infection in individual patients Source: Eur Respir J 2016; 47:1592-1594 Year: 2016 Benefit of treatment of latent tuberculosis infection in individual patients Source: Eur Respir J 2016; 47:1594-1595 Year: 2016 Benefit of treatment of latent tuberculosis infection in individual patients Source: Eur Respir J 2015; 46: 1397-1406 Year: 2015 The incidence of tuberculosis in patients taking anti TNF alpha therapy Source: Annual Congress 2011 - Tuberculosis in immunocompromised hosts Year: 2011 Outcomes of treatment of latent tuberculosis infection in children with two different regimens Source: Eur Respir J 2006; 28: Suppl. 50, 487s Year: 2006 Treatment of latent tuberculosis infection with 6 months isoniazid therapy in pediatric population Source: Eur Respir J 2005; 26: Suppl. 49, 624s Year: 2005 A combinatorial dual-immunoassay predicts reactivation risk for patients with previously incomplete treatment for latent tuberculosis infection Source: International Congress 2016 – Active and latent tuberculosis: biomarkers Year: 2016 Comparison of compliance of two therapeutic regimens in treatment of latent tuberculosis infection in Belgrade children Source: Eur Respir J 2004; 24: Suppl. 48, 648s Year: 2004 Tolerability of rifapentine-based regimens in latent tuberculosis infection treatment in the elderly Source: Eur Respir J, 53 (3) 1802396; 10.1183/13993003.02396-2018 Year: 2019 The assessment of the efficacy of a standard chemotherapy regimen in the treatment of new sputum-positive tuberculosis (TB) patients Source: Eur Respir J 2001; 18: Suppl. 33, 340s Year: 2001 Cost-effectiveness of interferon-γ release assay testing for the treatment of latent tuberculosis Source: Eur Respir J 2007; 30: 321-332 Year: 2007 Comparison of effector T-cell responses in patients with active TB disease compared to latent TB infection Source: Annual Congress 2007 - New perspectives and old problems in diagnosing tuberculosis infection and disease Year: 2007 IP-10 decreases during antituberculous treatment in children with active tuberculosis. Source: Virtual Congress 2020 – Tuberculosis: part 2 Year: 2020 Screening tests for latent tuberculosis prior to anti-TNF alpha therapy – a systematic review and meta-analysis Source: International Congress 2019 – Tuberculosis and comorbidities Year: 2019 Prevalence, screening and treatment of latent tuberculosis among oral corticosteroid recipients Source: Eur Respir J 2014; 44: 1373-1375 Year: 2014 The relapses of tuberculosis with multiple drug resistance among patients treated under DOTS-Plus regimen Source: Annual Congress 2010 - Tuberculosis drug resistance Year: 2010 The incidence of multi drug resistant tuberculosis among patients receiving standardized treatment regimen for suspected MDR-TB Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012 Anti-TNF-alpha therapy in patients with latent tuberculosis incidence Source: International Congress 2015 – Screening strategies in TB Year: 2015